

August 20, 2026

[REDACTED]
Administrator
Cross Keys Village-The Brethren Home Community
2990 Carlisle Pike
New Oxford, Pennsylvania 17350

[REDACTED]
RE: Cross Keys Village-The Brethren Home Community

License #: 342870

Dear [REDACTED]

Thank you for your request for a waiver of 55. Pa. Code § 2600 (relating to personal care homes). You have requested to waive 55 Pa.Code § 2600.190(b) (relating to medication administration training) to allow unlicensed direct care staff to administer subcutaneous injections of GLP-1 agonist medications.

2600.190 Medication Administration Training

(b) A staff person is permitted to administer insulin injections following successful completion of a Department-approved medications administration course that includes the passing of a written performance-based competency test within the past 2 years, as well as successful completion of a Department-approved diabetes patient education program within the past 12 months.

This waiver is granted under the following conditions:

1. Each medication technician who will administer subcutaneous injections of GLP-1 agonist medications must successfully complete and pass the Department of Human Service's medication administration course; receive in-person training on administering subcutaneous injections from a licensed health care professional and receive training on the specific medication being administered, including potential side effects, medication interactions, and appropriate observation and reporting from a licensed health care professional.

2. Each medication technician who will administer subcutaneous injections of GLP-1 agonist medications must have four hours of annual training related to GLP-1 agonist medications, and diabetes management
3. The initial training required by this waiver fulfills the requirements for annual training during the training year in which this waiver was issued. For subsequent training years, the annual training requirements must be met within your facility's predetermined training year.
4. The home must utilize a process for monitoring, evaluating, and documenting the administration of subcutaneous injection of the GLP-1 agonist medications.
5. A policy regarding the administration of subcutaneous injection of GLP-1 agonist medications including written procedures for administration, documentation, monitoring, evaluating, observation, and reporting must be developed and provided to all medication technician(s) who will administer these medications as part of their training.
6. The facility must have a licensed clinical contact available at all times to answer any questions regarding the administration of subcutaneous injection of GLP-1 agonist medications. The licensed clinical contact must be an employee of the facility or under contract.

Sincerely,

Theresa Hartman

Theresa Hartman, RN, CCM
Bureau Director, Human Services Licensing
Office of Long-Term Living
Department of Human Services

